Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OncoTherapy Science Inc Announces Result of Phase II Study of Single-agent Gemcitabine in Patients with Biliary Tract Cancer


Monday, 30 Sep 2013 08:00pm EDT 

OncoTherapy Science Inc announced that it has disclosed the result of phase II study of single-agent gemcitabine in patients with biliary tract cancer. From July 2009 to June 2011, 55 patients were registered from 14 facilities all over the Japan and 54 were treated. For full analysis set of 54 patients, mean pt age was 62.9 years. Types of cancer patients had were: extrahepatic bile duct cancer, 13 pts; intrahepatic bile duct cancer, 20 pts; gallbladder cancer, 18 pts; and ampulla of Vater cancer, 3 pts. Median survival time was 10.05 months (95%CI: 7.95-13.96) in OTS102+GEM group, whereas it was 7.6 months in GEM alone group (log-rank test, p=0.043).(1-year survival rate, 44.4% vs 25.0%,respectively). 

Company Quote

240.0
40.0 +20.00%
24 Oct 2014